These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 32752060)
1. Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis. Cabibbo G; Celsa C; Enea M; Battaglia S; Rizzo GEM; Grimaudo S; Matranga D; Attanasio M; Bruzzi P; Craxì A; Cammà C Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32752060 [No Abstract] [Full Text] [Related]
2. First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials. Cabibbo G; Reig M; Celsa C; Torres F; Battaglia S; Enea M; Rizzo GEM; Petta S; Calvaruso V; Di Marco V; Craxì A; Singal AG; Bruix J; Cammà C Liver Cancer; 2022 Jan; 11(1):75-84. PubMed ID: 35222509 [TBL] [Abstract][Full Text] [Related]
3. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. Han Y; Zhi WH; Xu F; Zhang CB; Huang XQ; Luo JF World J Gastroenterol; 2021 May; 27(19):2415-2433. PubMed ID: 34040331 [TBL] [Abstract][Full Text] [Related]
4. First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination. Tella SH; Kommalapati A; Mahipal A; Jin Z Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740326 [TBL] [Abstract][Full Text] [Related]
5. Navigating the new landscape of second-line treatment in advanced hepatocellular carcinoma. Rimassa L; Wörns MA Liver Int; 2020 Aug; 40(8):1800-1811. PubMed ID: 32432830 [TBL] [Abstract][Full Text] [Related]
6. Current treatment options for hepatocellular carcinoma. Eugen K Klin Onkol; 2020; 33(Supplementum 3):20-25. PubMed ID: 33213161 [TBL] [Abstract][Full Text] [Related]
7. Systemic therapies for hepatocellular carcinoma: the present and the future. Celsa C; Giuffrida P; Stornello C; Grova M; Spatola F; Rizzo GEM; Busacca A; Cannella R; Battaglia S; Cammà C; Cabibbo G Recenti Prog Med; 2021 Feb; 112(2):110-116. PubMed ID: 33624623 [TBL] [Abstract][Full Text] [Related]
8. Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update. Kudo M Liver Cancer; 2020 Dec; 9(6):640-662. PubMed ID: 33442538 [TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study. Yoo C; Kim JH; Ryu MH; Park SR; Lee D; Kim KM; Shim JH; Lim YS; Lee HC; Lee J; Tai D; Chan SL; Ryoo BY Liver Cancer; 2021 Apr; 10(2):107-114. PubMed ID: 33977087 [TBL] [Abstract][Full Text] [Related]
10. Sequential Systemic Treatment in Advanced Hepatocellular Carcinoma Is Able to Prolong Median Survival to More than 3 Years in a Selected Real-World Cohort. von Felden J; Karkmann K; Ittrich H; Gil-Ibanez I; Fründt T; Krause J; Lohse AW; Wege H; Schulze K Visc Med; 2021 Mar; 37(2):87-93. PubMed ID: 33981749 [TBL] [Abstract][Full Text] [Related]
12. Sequential systemic treatment in patients with hepatocellular carcinoma. Kirstein MM; Scheiner B; Marwede T; Wolf C; Voigtländer T; Semmler G; Wacker F; Manns MP; Hinrichs JB; Pinter M; Vogel A Aliment Pharmacol Ther; 2020 Jul; 52(1):205-212. PubMed ID: 32432799 [TBL] [Abstract][Full Text] [Related]
13. Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date. Tella SH; Mahipal A; Kommalapati A; Jin Z Onco Targets Ther; 2019; 12():10335-10342. PubMed ID: 31819517 [TBL] [Abstract][Full Text] [Related]
14. A concise review of the changing landscape of hepatocellular carcinoma. Draper A Am J Manag Care; 2020 Oct; 26(10 Suppl):S211-S219. PubMed ID: 33052638 [TBL] [Abstract][Full Text] [Related]
15. HCC and Molecular Targeting Therapies: Back to the Future. Rinaldi L; Vetrano E; Rinaldi B; Galiero R; Caturano A; Salvatore T; Sasso FC Biomedicines; 2021 Sep; 9(10):. PubMed ID: 34680462 [TBL] [Abstract][Full Text] [Related]
16. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574 [TBL] [Abstract][Full Text] [Related]